Open AccessDetection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
Author(s) -
Takayuki Takahama,
Kazuko Sakai,
Masayuki Takeda,
Koichi Azuma,
Toyoaki Hida,
Masataka Hirabayashi,
Tetsuya Oguri,
Hiroshi Tanaka,
Noriyuki Ebi,
Toshiyuki Sawa,
Akihiro Bessho,
Motoko Tachihara,
Hiroaki Akamatsu,
Shuji Bandoh,
Daisuke Himeji,
Tetsuya Ohira,
Mototsugu Shimokawa,
Yoichi Nakanishi,
Kazuhiko Nakagawa,
Kazuto Nishio
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.11303
Subject(s) - t790m , medicine , digital polymerase chain reaction , liquid biopsy , lung cancer , gefitinib , resistance mutation , osimertinib , oncology , epidermal growth factor receptor , concordance , mutation , erlotinib , cancer research , cancer , pathology , gene , biology , polymerase chain reaction , reverse transcriptase , genetics
Next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to overcome resistance to earlier generations of such drugs mediated by a secondary T790M mutation of EGFR, but the performance of a second tumor biopsy to assess T790M mutation status can be problematic.